Cargando…
Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570210/ https://www.ncbi.nlm.nih.gov/pubmed/37665503 http://dx.doi.org/10.1007/s40273-023-01315-1 |
| _version_ | 1785119712414269440 |
|---|---|
| author | Otten, Thomas Riemsma, Rob Wijnen, Ben Armstrong, Nigel Stirk, Lisa Gordon, Caroline Ramaekers, Bram Kleijnen, Jos Joore, Manuela Grimm, Sabine |
| author_facet | Otten, Thomas Riemsma, Rob Wijnen, Ben Armstrong, Nigel Stirk, Lisa Gordon, Caroline Ramaekers, Bram Kleijnen, Jos Joore, Manuela Grimm, Sabine |
| author_sort | Otten, Thomas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10570210 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105702102023-10-14 Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Otten, Thomas Riemsma, Rob Wijnen, Ben Armstrong, Nigel Stirk, Lisa Gordon, Caroline Ramaekers, Bram Kleijnen, Jos Joore, Manuela Grimm, Sabine Pharmacoeconomics Correction Springer International Publishing 2023-09-04 2023 /pmc/articles/PMC10570210/ /pubmed/37665503 http://dx.doi.org/10.1007/s40273-023-01315-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Otten, Thomas Riemsma, Rob Wijnen, Ben Armstrong, Nigel Stirk, Lisa Gordon, Caroline Ramaekers, Bram Kleijnen, Jos Joore, Manuela Grimm, Sabine Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| title | Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| title_full | Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| title_fullStr | Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| title_full_unstemmed | Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| title_short | Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| title_sort | correction: belimumab for treating active autoantibody‑positive systemic lupus erythematosus: an evidence review group perspective of a nice single technology appraisal |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570210/ https://www.ncbi.nlm.nih.gov/pubmed/37665503 http://dx.doi.org/10.1007/s40273-023-01315-1 |
| work_keys_str_mv | AT ottenthomas correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT riemsmarob correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT wijnenben correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT armstrongnigel correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT stirklisa correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT gordoncaroline correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT ramaekersbram correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT kleijnenjos correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT jooremanuela correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal AT grimmsabine correctionbelimumabfortreatingactiveautoantibodypositivesystemiclupuserythematosusanevidencereviewgroupperspectiveofanicesingletechnologyappraisal |